Health Care Innovation
Health Care
NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars
Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market ...
Blog
Getting the Drug Spending Facts Right
In a typical rant, Senator Sanders claimed in a September 15th press release that “at a time when the drug companies are charging us by far the highest prices in the world, Congress must demand that Medicare negotiate prices with this extremely greedy and powerful industry.” The Senator clearly misunderstands ...
Featured
New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes
Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system ...
Commentary
Drug Price Controls Inflict Worse Harm Than Even Critics Recognize
It’s no secret that H.R. 3 — the Democrats’ plan to impose price controls on prescription drugs — would have devastating consequences for our healthcare sector. After all, artificially restricting the price of any product invariably leads to shortages, rationing, and a slowdown in both investment and innovation. A new ...
Commentary
We Should Not Lose Sight of the Upcoming Flu Season
As the Food and Drug Administration contemplates booster shots and a myriad of other regulatory issues related to the COVID-19 vaccine, it is essential to reiterate the importance of a vaccine that is available and recommended for every age group at no cost to the patient — the influenza vaccine. ...
Commentary
Biden’s Prescription Drug Plan Is Nothing More Than Price Controls
The Biden administration’s “Comprehensive Plan for Addressing High Drug Prices,” released last week, paints a vivid picture of the difficulties patients face affording their medicines. “Americans pay too much for prescription drugs,” the report notes. “Many Americans do not take medications as prescribed because of their cost.” How does the administration intend to ...
Featured
Watch: PRI Expert Discusses Biden Prescription Drug Plan
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss how the Biden plan to lower prescription drug costs is disappointing and would lead to less access and higher costs for patients with Scripps National News.
Commentary
Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented
The Congressional Budget Office just released an analysis of House Democrats’ effort to impose price controls on prescription drugs, H.R. 3 — the Elijah E. Cummings Lower Drug Costs Now Act. The CBO’s chief finding is grim. By drastically limiting pharmaceutical revenue, H.R. 3 would starve scientists of the funding they need ...
Drug Pricing
Watch Wayne Winegarden Discuss Drug Pricing Reform with Scripps National News
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the ...
Commentary
Let’s Not Repeat Canada’s Healthcare Mistakes
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars
Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market ...
Getting the Drug Spending Facts Right
In a typical rant, Senator Sanders claimed in a September 15th press release that “at a time when the drug companies are charging us by far the highest prices in the world, Congress must demand that Medicare negotiate prices with this extremely greedy and powerful industry.” The Senator clearly misunderstands ...
New PRI Series to Show How Flawed U.S. Health Insurance System Inflates Costs, Decreases Quality and Reduces Health Outcomes
Addressing the ongoing problems with the U.S. health insurance system, the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute today announced the release of the first paper in the Coverage Denied series, which will analyze and propose reforms to fix the problems in the current system ...
Drug Price Controls Inflict Worse Harm Than Even Critics Recognize
It’s no secret that H.R. 3 — the Democrats’ plan to impose price controls on prescription drugs — would have devastating consequences for our healthcare sector. After all, artificially restricting the price of any product invariably leads to shortages, rationing, and a slowdown in both investment and innovation. A new ...
We Should Not Lose Sight of the Upcoming Flu Season
As the Food and Drug Administration contemplates booster shots and a myriad of other regulatory issues related to the COVID-19 vaccine, it is essential to reiterate the importance of a vaccine that is available and recommended for every age group at no cost to the patient — the influenza vaccine. ...
Biden’s Prescription Drug Plan Is Nothing More Than Price Controls
The Biden administration’s “Comprehensive Plan for Addressing High Drug Prices,” released last week, paints a vivid picture of the difficulties patients face affording their medicines. “Americans pay too much for prescription drugs,” the report notes. “Many Americans do not take medications as prescribed because of their cost.” How does the administration intend to ...
Watch: PRI Expert Discusses Biden Prescription Drug Plan
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss how the Biden plan to lower prescription drug costs is disappointing and would lead to less access and higher costs for patients with Scripps National News.
Under Dems’ Drug Pricing Plan, Dozens of New Meds Will Never Be Invented
The Congressional Budget Office just released an analysis of House Democrats’ effort to impose price controls on prescription drugs, H.R. 3 — the Elijah E. Cummings Lower Drug Costs Now Act. The CBO’s chief finding is grim. By drastically limiting pharmaceutical revenue, H.R. 3 would starve scientists of the funding they need ...
Watch Wayne Winegarden Discuss Drug Pricing Reform with Scripps National News
Watch Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation, discuss his recent study showing how a two-part drug pricing system would ensure prices more accurately reflect how patients value drugs with Scripps National News. The report aired on 60 television stations in 42 markets across the ...
Let’s Not Repeat Canada’s Healthcare Mistakes
Demonstrators in 50 cities across the country took the streets last month to demand a government takeover of America’s health system. The Democrats who control Washington are trying to give those activists what they’re asking for, albeit in piecemeal fashion. In recent weeks, they’ve proposed lowering Medicare’s eligibility age and adding dental, vision and hearing benefits ...
